Literature DB >> 3524801

Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.

B Persky, L E Ostrowski, P Pagast, A Ahsan, R M Schultz.   

Abstract

The ability of B16-F10 mouse melanoma cells to cross an amnion basement membrane was determined in the presence of strong inhibitors of both serine and cysteine proteases. The concentrations of inhibitors were at orders of magnitude higher than their Ki values to serine and cysteine proteases implicated in metastasis, thus ensuring a complete inhibition for tumor secreted proteases such as cathepsin B-like proteases, plasminogen activators, and plasmin. Under these conditions of high serine and cysteine protease inhibitor concentrations, no significant decrease in B16-F10 melanoma cell invasion through the amnion was observed. Separate experiments showed that the inhibitors were neither toxic to the cells nor degraded. The results show that neither tumor cell secreted cathepsin B-like proteases nor plasminogen activator have a controlling role in basement membrane crossing in this metastatic model. A possible role for tumor cell membrane proteases in basement membrane invasion, in which the substrates of the protease bind to receptor sites near a membrane associated proteolytic activity, is not eliminated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524801

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Diffusion of dextrans and microspheres in the human amniotic basement membrane model.

Authors:  B Persky; D M Grganto
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

2.  Low-molecular-weight membrane component inhibits the metastatic phenotype of B16-F10 melanoma.

Authors:  Z Keren; S J LeGrue
Journal:  Clin Exp Metastasis       Date:  1989 May-Jun       Impact factor: 5.150

3.  Characterization of a connective tissue degrading metalloproteinase from human small cell lung cancer cells.

Authors:  S Zucker; T Turpeeniemi-Hujanen; J M Wieman; R M Lysik
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

Review 4.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

Authors:  J E Testa; J P Quigley
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

5.  In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases.

Authors:  P Mignatti; R Tsuboi; E Robbins; D B Rifkin
Journal:  J Cell Biol       Date:  1989-02       Impact factor: 10.539

6.  Purification and characterization of tumor invasion-inhibiting factors.

Authors:  A Isoai; Y Giga-Hama; K Shinkai; M Mukai; H Akedo; H Kumagai
Journal:  Jpn J Cancer Res       Date:  1990-09

7.  Production of immunoreactive polymorphonuclear leucocyte elastase in human breast cancer cells: possible role of polymorphonuclear leucocyte elastase in the progression of human breast cancer.

Authors:  J I Yamashita; M Ogawa; S Ikei; H Omachi; S I Yamashita; T Saishoji; K Nomura; H Sato
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

8.  Breast cancer prognosis is poor when total plasminogen activator activity is low.

Authors:  J Yamashita; M Ogawa; K Inada; S Yamashita; Y Nakashima; T Saishoji; K Nomura
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.